Oncology Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
Oncology After Pluvicto: Alpha radiopharma and prostate cancer Dr Philip Kantoff, a world-renowned prostate cancer clinician and researcher, discusses alpha radiopharma treatment possibilities.
News Novartis reveals more data behind Pluvicto expansion bid Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
Oncology Radiopharmaceutical development is accelerating. Preclinical... Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Market Access Five Takeaways from JP Morgan Week 2026 JP Morgan Week may not have produced megadeals this year, but it still yielded plenty of food for thought. Here's five quick insights from San Fran.
Oncology Radiopharmaceutical innovation: Giving cancer drugs second c... Molecular recycling could transform the economics and innovation of oncology drug discovery.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.